Padmaja Polam

发表

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

M. Bower, R. Wynn, Q. Wang, 2017, ACS medicinal chemistry letters.

Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B*

Richard Wynn, Mary Becker-Pasha, R. Wynn, 2006, Journal of Biological Chemistry.

Structural Basis for Inhibition of Protein-tyrosine Phosphatase 1B by Isothiazolidinone Heterocyclic Phosphonate Mimetics*

Michael Bower, Richard Wynn, Ronald Klabe, 2006, Journal of Biological Chemistry.

Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics.

Zelda R. Wasserman, Paul J. Ala, Ronald M. Klabe, 2006 .

Selective inhibition of indoleamine 2 , 3-dioxygenase ( IDO 1 ) effectively regulates mediators of antitumor immunity

R. Wynn, Q. Wang, J. Fridman, 2010 .

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).

H. Koblish, P. Scherle, T. Maduskuie, 2019, ACS medicinal chemistry letters.

Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors.

R. Wynn, Wenyu Zhu, Phillip C. C. Liu, 2007, Bioorganic & medicinal chemistry letters.

Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics.

Karl Blom, Michael Bower, James Pruitt, 2005, Journal of medicinal chemistry.

Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.

M. Bower, R. Wynn, Wenyu Zhu, 2006, Journal of medicinal chemistry.

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

Qian Wang, Beth Thomas, Richard Wynn, 2010, Blood.

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

Jun Yu Li, R. Wynn, X. Liu, 2018, Clinical Cancer Research.

Abstract 3523: Discovery of a novel BET inhibitor INCB054329

R. Wynn, X. Liu, Jun Li, 2015 .